drugset / Trial / NCT00091273
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.
Timeline
- Start
- 2004-06
- Primary completion
- 2006-02
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ovarian cancer peptide vaccine | Vaccine | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Background | tetanus toxoid helper peptide | Peptide | — | Subcutaneous |